DEXCOM INC — Director's Dealing 2023

Mar 14, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2023-03-10

Reporting Person: Balo Andrew K (EVP Regulatory Strategy Clinic)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-10	Common Stock	D	3275	$111.399	Disposed	59303	Direct
2023-03-10	Common Stock	D	2405	$111.399	Disposed	56898	Direct
2023-03-10	Common Stock	D	5990	$111.399	Disposed	50908	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	30212	Indirect

Footnotes

F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2: Included in this number are 20,356 unvested restricted stock units, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

F3: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee.